Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity

Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity-related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevent...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American Heart Association Vol. 12; no. 11; p. e029282
Main Authors Michos, Erin D, Lopez-Jimenez, Francisco, Gulati, Martha
Format Journal Article
LanguageEnglish
Published England John Wiley and Sons Inc 06.06.2023
Wiley
Subjects
Contemporary Review
GLP‐1 RA
obesity
overweight
weight loss
weight loss
GLP‐1 RA
overweight
obesity
Online AccessGet full text

Cover

Abstract Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity-related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevention of CVD in patients with overweight or obesity. The recently demonstrated efficacy of some pharmacologic therapies for chronic weight management may encourage health care professionals to recognize obesity as a treatable serious chronic disease and motivate patients to re-engage with weight loss when previous attempts have been ineffective or unsustainable. This review article summarizes the benefits and challenges associated with lifestyle changes, bariatric surgery, and historical pharmacologic interventions in the treatment of obesity, and focuses on the current evidence for the efficacy and safety of the newer glucagon-like peptide-1 receptor agonist medications in the management of obesity and potential reduction of CVD risk. We conclude that the available evidence demonstrates glucagon-like peptide-1 receptor agonists should be strongly considered in clinical practice for the treatment of obesity and reduction of CVD risk in people with type 2 diabetes. If ongoing research proves glucagon-like peptide-1 receptor agonists to be effective in reducing the risk of CVD onset in patients with obesity, irrespective of type 2 diabetes status, it will herald a new treatment paradigm in this setting, and now is the time for health care professionals to better recognize the benefits of these agents.
AbstractList Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD mortality are major obesity‐related complications, and management guidelines now recommend weight loss as a key strategy for the primary prevention of CVD in patients with overweight or obesity. The recently demonstrated efficacy of some pharmacologic therapies for chronic weight management may encourage health care professionals to recognize obesity as a treatable serious chronic disease and motivate patients to re‐engage with weight loss when previous attempts have been ineffective or unsustainable. This review article summarizes the benefits and challenges associated with lifestyle changes, bariatric surgery, and historical pharmacologic interventions in the treatment of obesity, and focuses on the current evidence for the efficacy and safety of the newer glucagon‐like peptide‐1 receptor agonist medications in the management of obesity and potential reduction of CVD risk. We conclude that the available evidence demonstrates glucagon‐like peptide‐1 receptor agonists should be strongly considered in clinical practice for the treatment of obesity and reduction of CVD risk in people with type 2 diabetes. If ongoing research proves glucagon‐like peptide‐1 receptor agonists to be effective in reducing the risk of CVD onset in patients with obesity, irrespective of type 2 diabetes status, it will herald a new treatment paradigm in this setting, and now is the time for health care professionals to better recognize the benefits of these agents.
Author Lopez-Jimenez, Francisco
Gulati, Martha
Michos, Erin D
AuthorAffiliation 1 Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD USA
2 Division of Preventive Cardiology, Department of Cardiovascular Medicine Mayo College of Medicine Rochester MN USA
3 Barbra Streisand Women’s Heart Center Cedars‐Sinai Smidt Heart Institute Los Angeles CA USA
AuthorAffiliation_xml – name: 1 Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD USA
– name: 3 Barbra Streisand Women’s Heart Center Cedars‐Sinai Smidt Heart Institute Los Angeles CA USA
– name: 2 Division of Preventive Cardiology, Department of Cardiovascular Medicine Mayo College of Medicine Rochester MN USA
Author_xml – sequence: 1
  givenname: Erin D
  orcidid: 0000-0002-5547-5084
  surname: Michos
  fullname: Michos, Erin D
  organization: Division of Cardiology Johns Hopkins University School of Medicine Baltimore MD USA
– sequence: 2
  givenname: Francisco
  orcidid: 0000-0001-5788-9734
  surname: Lopez-Jimenez
  fullname: Lopez-Jimenez, Francisco
  organization: Division of Preventive Cardiology, Department of Cardiovascular Medicine Mayo College of Medicine Rochester MN USA
– sequence: 3
  givenname: Martha
  orcidid: 0000-0003-0735-9756
  surname: Gulati
  fullname: Gulati, Martha
  organization: Barbra Streisand Women's Heart Center Cedars-Sinai Smidt Heart Institute Los Angeles CA USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37278394$$D View this record in MEDLINE/PubMed
BookMark eNpVks1u3CAUha0qVfPTrLurWHbjCRhsYFWNRm0y1UgTRa2yRBhfe0ht44I9VV6kzxtmnEYJG644534XwTlPTnrXQ5J8InhBSEGufixvlguSZQucyUxk75KzDDOeSinwyav6NLkM4QHHVWSc5vJDckp5xgWV7Cz5d-daQK5G1-1kdOP6dGN_A7qFYbQVpATdgYm182gZRRvGgGyPlmZnYW_7Bt2DbXYj2rgQkO4rtO4G747KSvvKur0OZmq1R9tpNK6DY_stuCFOvbfjDm334P_OkEP_toRgx8ePyftatwEun_eL5Nf3bz9XN-lme71eLTepYQUe05qWNWBeC8hkkZdYMo5riescCJiSEFrxaJAF0TkwCpyUhAkpa8l1gaHK6EWynrmV0w9q8LbT_lE5bdXxwPlGaT9a04ISTApdVdgIXjKNmSg4llIazEyOSyIi6-vMGqayg8pAP3rdvoG-VXq7U43bK4KpIJKzSPjyTPDuzwRhVJ0NBtpW9-CmoOInU8woYzRar2ar8fHpPdQvcwhWh3SoQzpUTIea0xE7Pr--3ov_fxboE3VvuNU
CitedBy_id crossref_primary_10_1007_s00228_024_03646_0
crossref_primary_10_3390_ph17020199
crossref_primary_10_1016_j_metabol_2023_155655
crossref_primary_10_14309_ajg_0000000000002820
crossref_primary_10_1016_j_jacl_2024_05_005
crossref_primary_10_1097_WNO_0000000000002133
crossref_primary_10_1016_j_cpcardiol_2024_102403
crossref_primary_10_1016_j_metabol_2024_155955
crossref_primary_10_7326_AITC202406180
crossref_primary_10_1016_j_ajpc_2024_100651
Cites_doi 10.1161/CIR.0000000000000678
10.1001/jamasurg.2020.0087
10.1056/NEJMoa1003114
10.1001/jamasurg.2013.3654
10.1097/FJC.0000000000000864
10.1002/oby.22769
10.3390/nu5041218
10.1016/j.ahj.2010.07.023
10.1038/sj.ijo.0802831
10.1002/oby.21107
10.1016/S2213-8587(16)30162-0
10.1038/nrendo.2012.140
10.1093/eurheartj/ehac071
10.1038/ijo.2013.120
10.1056/NEJMoa2032183
10.1016/j.ahj.2020.07.008
10.1056/NEJMsa1909301
10.2337/dc20-2977
10.1056/NEJMoa2108269
10.1001/jamahealthforum.2021.4182
10.1056/NEJMoa1411892
10.1038/ijo.2016.67
10.1111/obr.13435
10.1007/s11883-014-0445-x
10.1093/ajcn/80.6.1461
10.1002/oby.22054
10.1161/01.cir.0000437739.71477.ee
10.1097/XCE.0000000000000195
10.1161/CIRCULATIONAHA.118.036811
10.1111/dom.14707
10.1007/s12325-021-01710-0
10.2337/dc20-S010
10.1111/dom.14725
10.1007/s11695-022-06332-1
10.1001/jama.2015.9676
10.1016/j.cmet.2013.04.008
10.1038/oby.2011.330
10.1177/2042018819897527
10.1210/jcem.87.3.8355
10.1001/jama.2021.1831
10.1056/NEJMoa1607141
10.2337/dc10-2415
10.1056/NEJMoa2206038
10.1210/clinem/dgaa006
10.1186/1471-2458-9-88
10.1016/S0140-6736(97)11509-4
10.1007/s00125-013-3145-0
10.1056/NEJMoa1901118
10.1016/j.jdiacomp.2020.107548
10.1093/fampra/cmab169
10.1056/NEJMoa1614362
10.1056/NEJMoa1808721
10.1016/j.pcad.2017.09.001
10.1210/en.2009-1272
10.1038/s41366-022-01176-2
10.1037/0003-066X.62.3.220
10.1161/JAHA.121.023811
10.1016/j.jacc.2015.03.002
10.1161/JAHA.121.022930
10.1056/NEJM199708283370901
10.3945/ajcn.111.024927
10.2337/ds017-0025
10.1093/bjs/znab245
10.1001/jama.2016.1558
10.1056/NEJMoa1509225
10.1161/STR.0000000000000375
10.1016/S0140-6736(21)00213-0
10.1056/NEJMoa0909809
10.1016/j.jviscsurg.2017.10.012
10.1056/NEJMoa1612917
10.1016/S0140-6736(10)60935-X
10.1038/s41366-021-00788-4
10.1111/dom.13125
10.1093/eurjpc/zwac187
10.3390/metabo11020073
10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
10.1016/S0140-6736(18)32261-X
10.1016/S2213-8587(21)00203-5
10.1093/europace/euy117
10.1056/NEJMra1514009
10.4158/EP161365.GL
10.1161/CIR.0000000000000973
10.1056/NEJMoa1203858
10.1080/17512433.2021.1933433
10.1016/S0140-6736(11)60205-5
10.1056/NEJMoa1603827
10.1210/en.2013-1934
10.1001/jama.2021.3224
10.1080/00325481.2021.2002616
10.1016/S0140-6736(19)31149-3
10.1016/j.clnesp.2022.03.020
ContentType Journal Article
Copyright 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
Copyright_xml – notice: 2023 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.
DBID NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1161/JAHA.122.029282
DatabaseName PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList CrossRef

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate GLP‐1 RAs in Weight Loss and Cardiovascular Health
EISSN 2047-9980
EndPage e029282
ExternalDocumentID oai_doaj_org_article_8498add0c87b4a048670999c04c50b18
10_1161_JAHA_122_029282
37278394
Genre Journal Article
Review
GrantInformation_xml – fundername: ;
GroupedDBID 0R~
1OC
24P
53G
5VS
8-1
AAZKR
ACGFO
ACXQS
ADBBV
ADKYN
ADZMN
AEGXH
AENEX
AIAGR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AVUZU
BAWUL
BCNDV
DIK
EBS
EMOBN
GODZA
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
NPM
OK1
RAH
RHF
RNS
RPM
WIN
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c460t-f3bfe07f8e2965b09470f90f5e1ecb113d7bfe961a5e43e71b14899f97a60ed23
IEDL.DBID RPM
ISSN 2047-9980
IngestDate Tue Oct 22 15:09:31 EDT 2024
Tue Sep 17 21:31:14 EDT 2024
Fri Oct 25 07:02:34 EDT 2024
Fri Aug 23 01:16:21 EDT 2024
Wed Oct 16 00:38:01 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords weight loss
GLP‐1 RA
overweight
obesity
Language English
License This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c460t-f3bfe07f8e2965b09470f90f5e1ecb113d7bfe961a5e43e71b14899f97a60ed23
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
For Sources of Funding and Disclosures, see page 11.
This article was sent to Tiffany M. Powell‐Wiley, MD, MPH, Guest Editor, for review by expert referees, editorial decision, and final disposition.
ORCID 0000-0003-0735-9756
0000-0002-5547-5084
0000-0001-5788-9734
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10381974/
PMID 37278394
PQID 2823043443
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_8498add0c87b4a048670999c04c50b18
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10381974
proquest_miscellaneous_2823043443
crossref_primary_10_1161_JAHA_122_029282
pubmed_primary_37278394
PublicationCentury 2000
PublicationDate 2023-06-06
PublicationDateYYYYMMDD 2023-06-06
PublicationDate_xml – month: 06
  year: 2023
  text: 2023-06-06
  day: 06
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Hoboken
PublicationTitle Journal of the American Heart Association
PublicationTitleAlternate J Am Heart Assoc
PublicationYear 2023
Publisher John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley and Sons Inc
– name: Wiley
References e_1_3_2_28_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_62_2
e_1_3_2_85_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_66_2
(e_1_3_2_78_2) 2014
e_1_3_2_100_2
e_1_3_2_104_2
e_1_3_2_81_2
(e_1_3_2_65_2) 2014
e_1_3_2_108_2
e_1_3_2_16_2
e_1_3_2_7_2
e_1_3_2_54_2
e_1_3_2_31_2
e_1_3_2_73_2
e_1_3_2_12_2
e_1_3_2_58_2
e_1_3_2_96_2
e_1_3_2_3_2
Fryar CD (e_1_3_2_2_2) 2020
e_1_3_2_35_2
e_1_3_2_92_2
e_1_3_2_50_2
e_1_3_2_48_2
e_1_3_2_29_2
e_1_3_2_40_2
e_1_3_2_86_2
e_1_3_2_21_2
e_1_3_2_44_2
e_1_3_2_25_2
e_1_3_2_67_2
e_1_3_2_103_2
(e_1_3_2_90_2) 2005
e_1_3_2_107_2
(e_1_3_2_64_2) 2017
e_1_3_2_17_2
e_1_3_2_59_2
e_1_3_2_6_2
e_1_3_2_32_2
e_1_3_2_51_2
e_1_3_2_74_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_55_2
e_1_3_2_97_2
e_1_3_2_93_2
e_1_3_2_70_2
e_1_3_2_111_2
e_1_3_2_26_2
e_1_3_2_49_2
(e_1_3_2_82_2) 2017
Sherman MM (e_1_3_2_38_2) 2016; 41
e_1_3_2_41_2
e_1_3_2_87_2
(e_1_3_2_63_2) 2010
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_68_2
e_1_3_2_60_2
e_1_3_2_102_2
e_1_3_2_106_2
e_1_3_2_9_2
e_1_3_2_37_2
Nargesi AA (e_1_3_2_110_2) 2021; 10
e_1_3_2_18_2
(e_1_3_2_89_2) 2016
e_1_3_2_75_2
e_1_3_2_10_2
e_1_3_2_52_2
e_1_3_2_5_2
e_1_3_2_33_2
e_1_3_2_79_2
e_1_3_2_14_2
e_1_3_2_56_2
e_1_3_2_98_2
e_1_3_2_94_2
e_1_3_2_71_2
(e_1_3_2_39_2) 2012
e_1_3_2_27_2
e_1_3_2_42_2
e_1_3_2_84_2
e_1_3_2_23_2
e_1_3_2_69_2
e_1_3_2_46_2
e_1_3_2_88_2
e_1_3_2_61_2
(e_1_3_2_77_2) 2017
e_1_3_2_80_2
e_1_3_2_101_2
e_1_3_2_109_2
e_1_3_2_105_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_53_2
e_1_3_2_76_2
(e_1_3_2_83_2) 2005
e_1_3_2_99_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_57_2
e_1_3_2_95_2
e_1_3_2_4_2
e_1_3_2_91_2
e_1_3_2_72_2
References_xml – ident: e_1_3_2_12_2
  doi: 10.1161/CIR.0000000000000678
– ident: e_1_3_2_25_2
  doi: 10.1001/jamasurg.2020.0087
– ident: e_1_3_2_32_2
  doi: 10.1056/NEJMoa1003114
– ident: e_1_3_2_23_2
  doi: 10.1001/jamasurg.2013.3654
– ident: e_1_3_2_111_2
  doi: 10.1097/FJC.0000000000000864
– ident: e_1_3_2_87_2
  doi: 10.1002/oby.22769
– ident: e_1_3_2_7_2
  doi: 10.3390/nu5041218
– volume-title: WEGOVY (Semaglutide) Injection. Prescribing Information
  year: 2017
  ident: e_1_3_2_77_2
– volume-title: ADLYXIN (Lixisenatide) Injection. Prescribing Information
  year: 2016
  ident: e_1_3_2_89_2
– ident: e_1_3_2_98_2
  doi: 10.1016/j.ahj.2010.07.023
– ident: e_1_3_2_97_2
  doi: 10.1038/sj.ijo.0802831
– ident: e_1_3_2_107_2
  doi: 10.1002/oby.21107
– volume-title: QYSMIA (Phentermine and Topiramate Extended‐Release) Capsules. Prescribing Information
  year: 2012
  ident: e_1_3_2_39_2
– ident: e_1_3_2_18_2
  doi: 10.1016/S2213-8587(16)30162-0
– ident: e_1_3_2_49_2
  doi: 10.1038/nrendo.2012.140
– ident: e_1_3_2_22_2
  doi: 10.1093/eurheartj/ehac071
– ident: e_1_3_2_70_2
  doi: 10.1038/ijo.2013.120
– ident: e_1_3_2_72_2
  doi: 10.1056/NEJMoa2032183
– ident: e_1_3_2_92_2
  doi: 10.1016/j.ahj.2020.07.008
– year: 2020
  ident: e_1_3_2_2_2
  article-title: Prevalence of overweight, obesity, and severe obesity among adults aged 20 and over: United States, 1960–1962 through 2017–2018
  publication-title: NCHS Health E‐Stats.
  contributor:
    fullname: Fryar CD
– ident: e_1_3_2_4_2
  doi: 10.1056/NEJMsa1909301
– ident: e_1_3_2_100_2
  doi: 10.2337/dc20-2977
– ident: e_1_3_2_61_2
  doi: 10.1056/NEJMoa2108269
– ident: e_1_3_2_101_2
  doi: 10.1001/jamahealthforum.2021.4182
– ident: e_1_3_2_52_2
– ident: e_1_3_2_69_2
  doi: 10.1056/NEJMoa1411892
– ident: e_1_3_2_43_2
  doi: 10.1038/ijo.2016.67
– volume-title: OZEMPIC (Semaglutide) Injection. Prescribing Information
  year: 2017
  ident: e_1_3_2_64_2
– ident: e_1_3_2_51_2
  doi: 10.1111/obr.13435
– ident: e_1_3_2_30_2
  doi: 10.1007/s11883-014-0445-x
– ident: e_1_3_2_36_2
  doi: 10.1093/ajcn/80.6.1461
– ident: e_1_3_2_96_2
  doi: 10.1002/oby.22054
– volume: 10
  year: 2021
  ident: e_1_3_2_110_2
  article-title: Contemporary national patterns of eligibility and use of novel cardioprotective antihyperglycemic agents in type 2 diabetes mellitus
  publication-title: JAMA
  contributor:
    fullname: Nargesi AA
– ident: e_1_3_2_16_2
  doi: 10.1161/01.cir.0000437739.71477.ee
– ident: e_1_3_2_105_2
  doi: 10.1097/XCE.0000000000000195
– ident: e_1_3_2_58_2
  doi: 10.1161/CIRCULATIONAHA.118.036811
– ident: e_1_3_2_76_2
  doi: 10.1111/dom.14707
– ident: e_1_3_2_50_2
  doi: 10.1007/s12325-021-01710-0
– ident: e_1_3_2_102_2
  doi: 10.2337/dc20-S010
– ident: e_1_3_2_84_2
  doi: 10.1111/dom.14725
– ident: e_1_3_2_3_2
– ident: e_1_3_2_28_2
  doi: 10.1007/s11695-022-06332-1
– ident: e_1_3_2_68_2
  doi: 10.1001/jama.2015.9676
– ident: e_1_3_2_106_2
  doi: 10.1016/j.cmet.2013.04.008
– ident: e_1_3_2_41_2
  doi: 10.1038/oby.2011.330
– ident: e_1_3_2_37_2
  doi: 10.1177/2042018819897527
– volume-title: Trulicity (Dulaglutide) Injection. Prescribing Information
  year: 2014
  ident: e_1_3_2_65_2
– ident: e_1_3_2_48_2
  doi: 10.1210/jcem.87.3.8355
– ident: e_1_3_2_74_2
  doi: 10.1001/jama.2021.1831
– ident: e_1_3_2_55_2
  doi: 10.1056/NEJMoa1607141
– ident: e_1_3_2_11_2
  doi: 10.2337/dc10-2415
– volume-title: Victoza® (liraglutide) Injection. Prescribing Information
  year: 2010
  ident: e_1_3_2_63_2
– ident: e_1_3_2_79_2
  doi: 10.1056/NEJMoa2206038
– ident: e_1_3_2_24_2
  doi: 10.1210/clinem/dgaa006
– ident: e_1_3_2_5_2
  doi: 10.1186/1471-2458-9-88
– ident: e_1_3_2_85_2
  doi: 10.1016/S0140-6736(97)11509-4
– ident: e_1_3_2_108_2
  doi: 10.1007/s00125-013-3145-0
– ident: e_1_3_2_56_2
  doi: 10.1056/NEJMoa1901118
– ident: e_1_3_2_95_2
  doi: 10.1016/j.jdiacomp.2020.107548
– ident: e_1_3_2_17_2
  doi: 10.1093/fampra/cmab169
– ident: e_1_3_2_9_2
  doi: 10.1056/NEJMoa1614362
– ident: e_1_3_2_34_2
  doi: 10.1056/NEJMoa1808721
– ident: e_1_3_2_67_2
  doi: 10.1016/j.pcad.2017.09.001
– ident: e_1_3_2_81_2
  doi: 10.1210/en.2009-1272
– ident: e_1_3_2_99_2
  doi: 10.1038/s41366-022-01176-2
– ident: e_1_3_2_21_2
  doi: 10.1037/0003-066X.62.3.220
– ident: e_1_3_2_104_2
  doi: 10.1161/JAHA.121.023811
– ident: e_1_3_2_14_2
  doi: 10.1016/j.jacc.2015.03.002
– ident: e_1_3_2_91_2
– ident: e_1_3_2_13_2
  doi: 10.1161/JAHA.121.022930
– ident: e_1_3_2_33_2
  doi: 10.1056/NEJM199708283370901
– volume-title: Saxenda (Liraglutide) Injection. Prescribing information
  year: 2014
  ident: e_1_3_2_78_2
– ident: e_1_3_2_40_2
  doi: 10.3945/ajcn.111.024927
– ident: e_1_3_2_19_2
  doi: 10.2337/ds017-0025
– ident: e_1_3_2_29_2
  doi: 10.1093/bjs/znab245
– ident: e_1_3_2_44_2
  doi: 10.1001/jama.2016.1558
– volume-title: BYETTA® (Exenatide) Injection. Prescribing Information
  year: 2005
  ident: e_1_3_2_90_2
– ident: e_1_3_2_53_2
  doi: 10.1056/NEJMoa1509225
– volume-title: BYDUREON® (Exenatide) Injection. Prescribing Information
  year: 2005
  ident: e_1_3_2_83_2
– ident: e_1_3_2_103_2
  doi: 10.1161/STR.0000000000000375
– ident: e_1_3_2_73_2
  doi: 10.1016/S0140-6736(21)00213-0
– ident: e_1_3_2_86_2
  doi: 10.1056/NEJMoa0909809
– ident: e_1_3_2_27_2
  doi: 10.1016/j.jviscsurg.2017.10.012
– ident: e_1_3_2_57_2
  doi: 10.1056/NEJMoa1612917
– ident: e_1_3_2_31_2
  doi: 10.1016/S0140-6736(10)60935-X
– volume: 41
  start-page: 164
  year: 2016
  ident: e_1_3_2_38_2
  article-title: Naltrexone/bupropion ER (Contrave): newly approved treatment option for chronic weight management in obese adults
  publication-title: PT.
  contributor:
    fullname: Sherman MM
– ident: e_1_3_2_10_2
  doi: 10.1038/s41366-021-00788-4
– ident: e_1_3_2_71_2
  doi: 10.1111/dom.13125
– ident: e_1_3_2_6_2
  doi: 10.1093/eurjpc/zwac187
– ident: e_1_3_2_93_2
  doi: 10.3390/metabo11020073
– ident: e_1_3_2_46_2
  doi: 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
– ident: e_1_3_2_45_2
– ident: e_1_3_2_59_2
  doi: 10.1016/S0140-6736(18)32261-X
– ident: e_1_3_2_62_2
  doi: 10.1016/S2213-8587(21)00203-5
– ident: e_1_3_2_15_2
  doi: 10.1093/europace/euy117
– ident: e_1_3_2_20_2
  doi: 10.1056/NEJMra1514009
– ident: e_1_3_2_26_2
  doi: 10.4158/EP161365.GL
– ident: e_1_3_2_8_2
  doi: 10.1161/CIR.0000000000000973
– ident: e_1_3_2_66_2
  doi: 10.1056/NEJMoa1203858
– volume-title: RYBELSUS (Semaglutide) Tablets. Prescribing Information
  year: 2017
  ident: e_1_3_2_82_2
– ident: e_1_3_2_94_2
  doi: 10.1080/17512433.2021.1933433
– ident: e_1_3_2_42_2
  doi: 10.1016/S0140-6736(11)60205-5
– ident: e_1_3_2_54_2
  doi: 10.1056/NEJMoa1603827
– ident: e_1_3_2_109_2
– ident: e_1_3_2_47_2
  doi: 10.1210/en.2013-1934
– ident: e_1_3_2_75_2
  doi: 10.1001/jama.2021.3224
– ident: e_1_3_2_35_2
– ident: e_1_3_2_80_2
  doi: 10.1080/00325481.2021.2002616
– ident: e_1_3_2_60_2
  doi: 10.1016/S0140-6736(19)31149-3
– ident: e_1_3_2_88_2
  doi: 10.1016/j.clnesp.2022.03.020
SSID ssj0000627359
Score 2.4624796
SecondaryResourceType review_article
Snippet Obesity remains a major public health problem, affecting almost half of adults in the United States. Increased risk of cardiovascular disease (CVD) and CVD...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage e029282
SubjectTerms Contemporary Review
GLP‐1 RA
obesity
overweight
weight loss
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELVQD4gL4puFtjISBy6hduJ8-LitWlZVSytE1d4s2xmzEShBbfben8CZn8cvYcZJVxuExIVjNvZmlDdevxnPvmHsLUmyWF1AEkBAoiSExIUsTyxunUUeNc4pD3n6sVhcqOOr_Gqj1RfVhA3ywMOL26uUrnANCl-VTtkoEEekxgvlc-Hk8DdfoTeCqeE3GLflXI9aPshq9o7nC0r8pe9FqtMqnWxDUa3_bxTzz0rJja3n6BF7OHJGPh9sfczuQfuE3T8dT8Wfsp-fum_Au8A_UAuzL1376_bHSfMV-DmVrNSAl5IjP8Sr7prPcQBie8Obls_9sgFKKfDLmCLlJ2gst23N18kGfjCpWOVnqx6dFOL081h-zi-bfsnPYoV1_BKaPzYceMYujg4_HyySsedC4lUh-iRkDlErQwUpYuUw-CtF0CLkIME7KbO6xAG6kDYHlUEpHcZTWgdd2kJAnWbP2VbbtfCScVzZpbdVTZwJw0aPTNT5oDQyoNzbVM3YuzsIzPdBWsPEkKSQhtAyiJYZ0JqxfYJoPYw0seMH6Clm9BTzL0-ZsTd3ABtcQ3QwYlvoVjcmjaeNmVLZjL0YAF8_KiupF4lGa6uJK0xsmd5pm2XU6SbteYnx2qv_Yf1r9oA63ccqtWKbbfXXK9hBPtS73ej6vwGfxgpJ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELWgSIgL4pstHzISBy4uduI48QGhpaKsqpZWiFV7sxxn3I2oErqbleCP8HsZO-lC0B64RXGcWHke-8149IaQ10GSxWoFzAMHJgV4Vvo0Yxa3TpVFjfMQhzz-rGZzeXienf8pBzT8wNVW1y7Uk5ovL_d-XP18jwb_Lhq8Em8Pp7MQ00v2eKLRg7hJbiUS3fSQxzdw_X5Zxp0604O8z5Z-o50pCvhvY53_Jk_-tRsd3CN3BxpJpz3u98kNaB6Q28fDQflD8utLewm09fRTqGp20TbsqP4G9DTksFTABEW6iNftkk6xEaFe0bqhU7eoIUQY6FmMmNIjHCi1TUU3sQe6P0pgpSfrDucsxO6nMRudntXdgp7EhOv4ktB_qD_wiMwPPn7dn7GhBANzUvGO-bREEHNfQILQlegL5txr7jMQ4Eoh0irHB7QSNgOZQi5KdK-09jq3ikOVpI_JTtM28JRQNPTc2aIKFAq9SIfEtHReaiREmbOJnJA317_ffO-VNkz0UJQwASmDSJkeqQn5EODZPBYksuONdnlhBoszhdQFLt7cFXkpbVQWDGzYcekyXopiQl5dg2vQpMI5iW2gXa9MEg8fUynTCXnSg735VJqH0iQaR1uMpsFoLOOWpl5E2e4gRS_Qfdv9jw8_I3dCXfuYk6aek51uuYYXyH668mWc1b8BaKwDwQ
  priority: 102
  providerName: Scholars Portal
Title Role of Glucagon-Like Peptide-1 Receptor Agonists in Achieving Weight Loss and Improving Cardiovascular Outcomes in People With Overweight and Obesity
URI https://www.ncbi.nlm.nih.gov/pubmed/37278394
https://search.proquest.com/docview/2823043443
https://pubmed.ncbi.nlm.nih.gov/PMC10381974
https://doaj.org/article/8498add0c87b4a048670999c04c50b18
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwEB4lOUS5VH2XPiJX6qEXdjGYh4_bVdNVlG1WVaPkhrB3nEVJINqw9_6EnPPz-ks6NrAKVU-9IAE2WPrG-Jvx8A3AJyvJUsgEfYMB-oKj8ZWJYr-gpTOJnca5jUPOvyezM3F8EV_sQNL_C-OS9rUqR9X1zagqVy638vZGj_s8sfFiPrWi3pyI8HgXdslCH_no7feXluRYdjo-xGjGx5OZDfqFoyCU5GIcwH6U2goTUgxWIyfa_y-m-XfC5KMV6OgpPOmoI5u0Q3wGO1g9h_15tzn-Ah5-1NfIasO-2Upml3X1-9f9SXmFbGEzV5ZIp5wRTaSzes0m1IAgvmNlxSZ6VaKNLLBzFyllJzRYVlRLto05sOkgcZWdbhqyVXTdFy4LnZ2XzYqdukRr9xDbv6s78BLOjr7-nM78rvSCr0USNL6JFIGXmgxDgkyRD5gGRgYmRo5acR4tU2ogE17EKCJMuSK3Skoj0yIJcBlGr2Cvqit8A4wmeKqLbGmpE3mPmgip0kZIIkKxLkLhwecegvy2VdjInWeS8NwClxNweQucB18sRNtmVhrbXajXl3lnIHkmZEYf7UBnqRKFUxS0LFgHQseB4pkHH3uAc5pKdn-kqLDe3OWh23SMhIg8eN0Cvn1VbzAeZANTGIxleIes18l199b69v-7voMDW-bepagl72GvWW_wA5GhRh26IAId5yI7dPPgD39eDeo
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LctMwFL1TykzphnfBPMUMCzZOLFt-aBkylFCSNsO0k-40liw3nrZ2J3U2rPgE1nweX8KVbGfqDhtYOpYcOzryPffq5AjgvbFkSXmk3Vx72mVU567Mg9BNMXRGofU4N3XI2WE0OWEHp-HpFkTdf2GsaF_JYlBeXA7KYmm1lVeXatjpxIbz2diYelMkwsM7cDc0V7uRpTdvYAzKIW-dfJDTDA9GE1P28weezzHJ2IWdIDZ7THDWi0fWtv9vXPO2ZPJGDNp_AIvu7hvpyflgXcuB-n7L2PHfH-8h3G9pKRk15x_Bli4fw86sXXh_Ar--VReaVDn5bHZJO6vK3z9-TotzTeZGFZNpPKQEKSgeVSsywgYIn2tSlGSkloU2VQuysFVYMsWfgaRlRjb1DDLuiWLJ0brGeaBt97lVuJNFUS_JkRVx24uY_u2eBk_hZP_T8Xjitts6uIpFXu3mgURgxHmifYSDxPwy9nLu5aGmWklKgyzGBjyiaahZoGMqMWXjPOdxGnk684M92C6rUj8Hgi-PWKVJZmgZZqYKya5UOeNIskKV-syBD93giqvGvUPYrCeiwkBCICREAwkHPprB3zQzttv2g2p1JtrREQnjCQYETyWxZKl1KzQMW3lMhZ6kiQPvOugInKZm7SUtdbW-Fr5d0AwYCxx41kBp81UdFB1IeiDr3Uv_DELHWoF3UHnx_13fwr3J8Wwqpl8Ov76EXR9JnJXCRa9gu16t9WskXbV8Y2fYHwA_LkM
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV27btswFCXaFDCy9P1QnyzQoYtkSqIeHF23rpvaiVE0SIAOhEiRsZBEMmx56dRP6NzP65f0kpKMKOiUURKp56HuuZcHhwi9M5YsGYuVqxVRLvWVdoUOIzeD0BlH1uPc1CHnh_H0mB6cRqetqnLTyipLKQqvvLj0ymJptZWrSznsdGLDxXxsTL19IMLDVa6Ht9EdGLQkvpKpN39hCMwRa918gNcMD0ZTU_oLPBIwSDT20SBMzDoTjPZikrXu_x_fvC6bvBKHJvfQj-4JGvnJubethSd_XjN3vNkj3kd3W3qKR02bB-iWKh-iwbydgH-E_nyrLhSuNP5sVks7q8q_v37PinOFF0YdkyvY9DFQUdiq1ngEDQBGG1yUeCSXhTLVC3xiq7F4Bq8CZ2WOd3UNPO6JY_HRtobxoGz3hVW645OiXuIjK-a2JzH927UNHqPjyafv46nbLu_gShqT2tWhAIAkOlUBwEJAnpkQzYiOlK-k8P0wT6ABi_0sUjRUiS8gdWNMsySLicqD8AnaK6tSPUMYfiKJzNLc0DPIUCWQXiE1ZUC2IpkF1EHvuw_MV42LB7fZT-xzAwsOsOANLBz0wQBg18zYb9sd1fqMt1-Ip5SlEBiITBNBM-taaJi2JFRGRPipg9528OEwXM0cTFaqarvhgZ3YDCkNHfS0gdPuUh0cHZT2gNa7l_4RgI-1BO_g8vzmXd-gweLjhM--HH59gfYD4HJWERe_RHv1eqteAfeqxWs7yP4BVcowww
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Role+of+Glucagon-Like+Peptide-1+Receptor+Agonists+in+Achieving+Weight+Loss+and+Improving+Cardiovascular+Outcomes+in+People+With+Overweight+and+Obesity&rft.jtitle=Journal+of+the+American+Heart+Association&rft.au=Michos%2C+Erin+D&rft.au=Lopez-Jimenez%2C+Francisco&rft.au=Gulati%2C+Martha&rft.date=2023-06-06&rft.eissn=2047-9980&rft.spage=e029282&rft.epage=e029282&rft_id=info:doi/10.1161%2FJAHA.122.029282&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2047-9980&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2047-9980&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2047-9980&client=summon